ICU (SeaStar Medical Holding) FCF Margin % : -7,004.48% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is SeaStar Medical Holding FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SeaStar Medical Holding's Free Cash Flow for the three months ended in Dec. 2024 was $-4.69 Mil. SeaStar Medical Holding's Revenue for the three months ended in Dec. 2024 was $0.07 Mil. Therefore, SeaStar Medical Holding's FCF Margin % for the quarter that ended in Dec. 2024 was -7,004.48%.

As of today, SeaStar Medical Holding's current FCF Yield % is -140.15%.

The historical rank and industry rank for SeaStar Medical Holding's FCF Margin % or its related term are showing as below:

ICU' s FCF Margin % Range Over the Past 10 Years
Min: -11857.04 Med: -11857.04 Max: -11857.04
Current: -11857.04

During the past 5 years, the highest FCF Margin % of SeaStar Medical Holding was -11857.04%. The lowest was -11857.04%. And the median was -11857.04%.

ICU's FCF Margin % is ranked worse than
93.45% of 1007 companies
in the Biotechnology industry
Industry Median: -127.22 vs ICU: -11857.04

SeaStar Medical Holding FCF Margin % Historical Data

The historical data trend for SeaStar Medical Holding's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SeaStar Medical Holding FCF Margin % Chart

SeaStar Medical Holding Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

-11,857.04

SeaStar Medical Holding Quarterly Data
	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial											-	-	-	-7,355.88	-7,004.48

Competitive Comparison of SeaStar Medical Holding's FCF Margin %

For the Biotechnology subindustry, SeaStar Medical Holding's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SeaStar Medical Holding's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's FCF Margin % distribution charts can be found below:

* The bar in red indicates where SeaStar Medical Holding's FCF Margin % falls into.

Save Embed

;

Save Embed

;

SeaStar Medical Holding FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

SeaStar Medical Holding's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-16.007	/	0.135
	=	-11,857.04 %

SeaStar Medical Holding's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-4.693	/	0.067
	=	-7,004.48 %

SeaStar Medical Holding FCF Margin % Related Terms

Thank you for viewing the detailed overview of SeaStar Medical Holding's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SeaStar Medical Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SeaStar Medical Holding Corp (NAS:ICU) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3513 Brighton Boulevard, Suite 410, Denver, CO, USA, 80216

Website

https://www.seastarmedical.com

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Executives

Kevin Chung	officer: Chief Medical Officer	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Heel Kenneth Van	director	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Richard D. Russell	director	3201 W BAY VISTA AVE, TAMPA FL 33611
Bruce M. Rodgers	director	302 KNIGHTS RUN AVE., STE. 1000, TAMPA FL 33602
Andres Lobo	director	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Caryl Baron	officer: See Remarks	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Eric Schlorff	director, officer: Chief Executive Officer	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Rick Barnett	director	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Allan Collins	director	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Dow Employees' Pension Plan Trust	10 percent owner	2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674
Union Carbide Employees' Pension Plan Trust	10 percent owner	2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674
Martin A Traber	director	100 N TAMPA STREET, SUITE 2700, TAMPA FL 33602
Lm Funding America, Inc.	10 percent owner	1200 WEST PLATT STREET, SUITE 100, TAMPA FL 33606
Craig E Burson	director	400 N. PARK AVENUE, UNIT 10B, BRECKENRIDGE CO 80424
Bruce H Bennett	director	3929 ARLINGTON DRIVE, PALM HARBOR FL 34685